Akero Therapeutics Inc
Change company Symbol lookup
Select an option...
AKRO Akero Therapeutics Inc
MRTX Mirati Therapeutics Inc
SIRC Solar Integrated Roofing Corp
CHSTY China High Speed Transmission Equipment Group Co Ltd
TTMZF Datable Technology Corp
WVFC W V S Financial Corp
WHLM Wilhelmina International Inc
SON Sonoco Products Co
VIRX Viracta Therapeutics Inc
PFS Provident Financial Services Inc
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Akero Therapeutics Inc. is a clinical-stage company that develops transformational treatments for patients with serious metabolic diseases. The Company is engaged to treat non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21 (FGF21), which is a hormone that protects against cellular stress and regulates the metabolism of lipids, carbohydrates and proteins throughout the body. EFX is being evaluated in two Phase IIb clinical trials in patients with biopsy-confirmed NASH: the study in pre-cirrhotic patients with F2-F3 fibrosis and the SYMMETRY study in cirrhotic patients with compensated F4 fibrosis. Its EFX program is focused on patients with cirrhotic NASH (F4, compensated) in Phase IIb clinical trial.

Closing Price
$41.54
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Below Average)
Volume:
504,619

10-day average volume:
611,670
504,619

KRBP ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 4, 2022 in the Class Action Filed on Behalf of Kiromic BioPharma, Inc. Shareholders

5:45 am ET October 4, 2022 (PR Newswire) Print

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Kiromic BioPharma, Inc. (NASDAQ: KRBP) alleging that the Company violated federal securities laws.

This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Kiromic common stock issued in connection with the Company's public offering that closed on July 2, 2021 and/or (b) Kiromic common stock between June 25, 2021 and August 13, 2021, both dates inclusive.Lead Plaintiff Deadline: October 4, 2022No obligation or cost to you.

Learn more about your recoverable losses in KRBP:https://www.kleinstocklaw.com/pslra-1/kiromic-biopharma-inc-loss-submission-form?id=32318&from=4

Kiromic BioPharma, Inc. NEWS - KRBP NEWS

CLASS ACTION CASE DETAILS: The complaint alleges that the registration statement and prospectus issued in connection with the Company's public offering that closed on July 2, 2021 (the "Offering Documents") failed to disclose that the Food and Drug Administration ("FDA") had, prior to the filing of these documents, imposed a clinical hold on the Company's Investigational New Drug ("IND") applications for its two new drug candidates. Given that the offering closed on July 2, 2021, more than thirty (30) days after the Company submitted the IND applications for its two immunotherapy product candidates, investors were assured that no clinical hold had been issued and clinical trials would commence.

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Kiromic you have until October 4, 2022 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased Kiromic securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the KRBP lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link: https://www.kleinstocklaw.com/pslra-1/kiromic-biopharma-inc-loss-submission-form?id=32318&from=4.

ABOUT KLEIN LAW FIRM

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:J. Klein, Esq.535 Fifth Avenue4th FloorNew York City, NY 10017jk@kleinstocklaw.comTelephone: (212) 616-4899www.kleinstocklaw.com

https://c212.net/c/img/favicon.png?sn=NY92030&sd=2022-10-04

View original content:https://www.prnewswire.com/news-releases/krbp-alert-the-klein-law-firm-announces-a-lead-plaintiff-deadline-of-october-4-2022-in-the-class-action-filed-on-behalf-of-kiromic-biopharma-inc-shareholders-301639724.html

SOURCE The Klein Law Firm

https://rt.prnewswire.com/rt.gif?NewsItemId=NY92030&Transmission_Id=202210040545PR_NEWS_USPR_____NY92030&DateId=20221004

comtex tracking

COMTEX_415882411/1005/2022-10-04T05:45:10

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.